Fujirebio Europe streamlines its organization

Company news

Gent, Belgium: April 4th 2014 - Fujirebio Europe today announced its intention to proceed with a reorganization in order to bring further focus and weight to the ongoing introduction of the LUMIPULSE® G1200 system on the European market, commenced in 2011. Fujirebio Europe has informed the Work’s Council in Gent about the estimated impact on employment and has communicated its intention to proceed for collective dismissal.

"Fujirebio Europe is engaged in a highly competitive market with the launch of our fully automated immunoassays analyzer LUMIPULSE® G1200, a market on which reduced public healthcare spending furthermore obliges companies to carefully streamline and optimize their organizations," says Christiaan De Wilde, CEO of Fujirebio Europe. "In this context a focused and smart organization is necessary. Of course  such decisions are always painful, particularly in organizations with a strong company history like ours. We will be working very closely with the social partners and employee representatives over the next weeks in order to find a respectful agreement for all parties."

Fujirebio Europe will continue to commercialize and support its historical strip-based and  specialized in vitro diagnostics (IVD) testing solutions (such as INNOTEST®, INNO-LiPA and INNO-LiATM) for which it remains one of the world leaders.

 
About Fujirebio

Fujirebio is a leading international healthcare company with a strong focus on high quality IVD testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.